Estimated EEG functional connectivity and aperiodic component induced by vagal nerve stimulation in patients with drug-resistant epilepsy.
EEG
aperiodic component
drug-resistant epilepsy (DRE)
functional connectivity (Fc)
vagus nerve stimulation (VNS)
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
08
2022
accepted:
28
10
2022
entrez:
12
12
2022
pubmed:
13
12
2022
medline:
13
12
2022
Statut:
epublish
Résumé
Vagal nerve stimulation (VNS) improves seizure frequency and quality of life in patients with drug-resistant epilepsy (DRE), although the exact mechanism is not fully understood. Previous studies have evaluated the effect of VNS on functional connectivity using the phase lag index (PLI), but none has analyzed its effect on EEG aperiodic parameters (offset and exponent), which are highly conserved and related to physiological functions. This study aimed to evaluate the effect of VNS on PLI and aperiodic parameters and infer whether these changes correlate with clinical responses in subjects with DRE. PLI, exponent, and offset were derived for each epoch (and each frequency band for PLI), on scalp-derived 64-channel EEG traces of 10 subjects with DRE, recorded before and 1 year after VNS. PLI, exponent, and offset were compared before and after VNS for each patient on a global basis, individual scalp regions, and channels and separately in responders and non-responders. A correlation analysis was performed between global changes in PLI and aperiodic parameters and clinical response. PLI (global and regional) decreased after VNS for gamma and delta bands and increased for an alpha band in responders, but it was not modified in non-responders. Aperiodic parameters after VNS showed an opposite trend in responders vs. non-responders: both were reduced in responders after VNS, but they were increased in non-responders. Changes in aperiodic parameters correlated with the clinical response. This study explored the action of VNS therapy from a new perspective and identified EEG aperiodic parameters as a new and promising method to analyze the efficacy of neuromodulation.
Sections du résumé
Background
UNASSIGNED
Vagal nerve stimulation (VNS) improves seizure frequency and quality of life in patients with drug-resistant epilepsy (DRE), although the exact mechanism is not fully understood. Previous studies have evaluated the effect of VNS on functional connectivity using the phase lag index (PLI), but none has analyzed its effect on EEG aperiodic parameters (offset and exponent), which are highly conserved and related to physiological functions.
Objective
UNASSIGNED
This study aimed to evaluate the effect of VNS on PLI and aperiodic parameters and infer whether these changes correlate with clinical responses in subjects with DRE.
Materials and methods
UNASSIGNED
PLI, exponent, and offset were derived for each epoch (and each frequency band for PLI), on scalp-derived 64-channel EEG traces of 10 subjects with DRE, recorded before and 1 year after VNS. PLI, exponent, and offset were compared before and after VNS for each patient on a global basis, individual scalp regions, and channels and separately in responders and non-responders. A correlation analysis was performed between global changes in PLI and aperiodic parameters and clinical response.
Results
UNASSIGNED
PLI (global and regional) decreased after VNS for gamma and delta bands and increased for an alpha band in responders, but it was not modified in non-responders. Aperiodic parameters after VNS showed an opposite trend in responders vs. non-responders: both were reduced in responders after VNS, but they were increased in non-responders. Changes in aperiodic parameters correlated with the clinical response.
Conclusion
UNASSIGNED
This study explored the action of VNS therapy from a new perspective and identified EEG aperiodic parameters as a new and promising method to analyze the efficacy of neuromodulation.
Identifiants
pubmed: 36504670
doi: 10.3389/fneur.2022.1030118
pmc: PMC9728998
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1030118Informations de copyright
Copyright © 2022 Coa, La Cava, Baldazzi, Polizzi, Pinna, Conti, Defazio, Pani and Puligheddu.
Déclaration de conflit d'intérêts
Unrelated to this study, in the past 3 years, Author RC received support for congress attendance from a distributor of VNS therapy and Author MP had a consulting contract with Livanova, USA. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Epilepsy Behav. 2017 Jan;66:4-9
pubmed: 27974275
Neuron. 2010 May 13;66(3):353-69
pubmed: 20471349
Epilepsy Behav. 2015 Dec;53:31-6
pubmed: 26515157
Nat Neurosci. 2020 Dec;23(12):1655-1665
pubmed: 33230329
J Neurophysiol. 2019 Dec 1;122(6):2427-2437
pubmed: 31619109
Nat Rev Neurosci. 2012 May 18;13(6):407-20
pubmed: 22595786
Med Hypotheses. 2010 May;74(5):855-6
pubmed: 20005054
Epilepsy Res. 2015 Jul;113:98-103
pubmed: 25986196
Hum Brain Mapp. 2007 Nov;28(11):1178-93
pubmed: 17266107
Clin Neurophysiol. 2005 Sep;116(9):2026-36
pubmed: 16055378
Clin EEG Neurosci. 2017 May;48(3):200-208
pubmed: 27287223
Epilepsia. 2017 Apr;58 Suppl 1:85-90
pubmed: 28386925
J Sleep Res. 2021 Oct;30(5):e13339
pubmed: 33769647
Sci Rep. 2018 Aug 16;8(1):12269
pubmed: 30115955
Brain Stimul. 2016 Jan-Feb;9(1):117-23
pubmed: 26460200
Int J Psychophysiol. 1999 Oct;34(1):5-20
pubmed: 10555870
Brain Connect. 2020 Dec;10(10):566-577
pubmed: 33073582
PLoS One. 2014 Oct 06;9(10):e108648
pubmed: 25286380
Front Neural Circuits. 2018 May 30;12:44
pubmed: 29899691
Neurosci Lett. 2013 Mar 1;536:14-8
pubmed: 23333601
Brain Res Bull. 2020 Oct;163:143-149
pubmed: 32745494
Neurosci Lett. 2014 Sep 19;580:153-7
pubmed: 25123446
Int J Neuropsychopharmacol. 2009 Oct;12(9):1209-21
pubmed: 19309534
Nat Rev Neurosci. 2009 Mar;10(3):186-98
pubmed: 19190637
J Neurosci. 2009 Oct 28;29(43):13613-20
pubmed: 19864573
Int J Mol Sci. 2019 Dec 08;20(24):
pubmed: 31817968
Brain Commun. 2021 May 14;3(2):fcab102
pubmed: 34131643
Comput Biol Med. 2020 May;120:103748
pubmed: 32421651
Epilepsy Res. 2016 Oct;126:141-6
pubmed: 27497814
J Neurophysiol. 2015 Jul;114(1):505-19
pubmed: 25855698
Seizure. 2005 Dec;14(8):527-33
pubmed: 16098769
Epilepsy Behav. 2008 Jul;13(1):25-31
pubmed: 18439878
Brain Topogr. 2019 Jul;32(4):643-654
pubmed: 27905073
Clin Neurophysiol. 2021 Jan;132(1):25-35
pubmed: 33248432
Neurology. 2001 Sep 11;57(5):879-84
pubmed: 11552020
Neurosci Biobehav Rev. 2017 Jun;77:286-300
pubmed: 28389343
Brain Res. 2018 Jul 15;1691:34-43
pubmed: 29679544
Dialogues Clin Neurosci. 2013 Sep;15(3):247-62
pubmed: 24174898
J Neural Eng. 2016 Jun;13(3):036015
pubmed: 27137952
Front Aging Neurosci. 2017 Jun 13;9:189
pubmed: 28659788
Epilepsy Res. 2017 Jul;133:46-53
pubmed: 28414968
J Comb Optim. 2009 Jan;17(1):74-97
pubmed: 21709753
Clin Neurophysiol. 2022 Oct;142:59-67
pubmed: 35970060
Neurol Med Chir (Tokyo). 2015;55(5):407-15
pubmed: 25925759
Epilepsia. 2010 Jun;51(6):1069-77
pubmed: 19889013
Epilepsia. 1998 Feb;39(2):201-5
pubmed: 9578001
PLoS One. 2017 May 3;12(5):e0175870
pubmed: 28467487
Neuroscience. 2006 Dec;143(3):793-803
pubmed: 17049178
Epilepsy Behav. 2013 Sep;28(3):374-8
pubmed: 23835092
Clin Neurophysiol. 2006 Oct;117(10):2111-7
pubmed: 16843722
Clin Neurophysiol. 2007 Aug;118(8):1877-88
pubmed: 17574912
Epilepsia. 2007 Feb;48(2):375-8
pubmed: 17295633